Daily Respiratory Research Analysis
Three high-impact studies advance respiratory infection science and preparedness: (1) a Science study establishes multi-species, multi-organ bat organoids that model zoonotic respiratory viruses and enable ex vivo antiviral testing; (2) a PNAS study maps shared human host genetic dependencies across nine respiratory viruses and validates STT3A/B as broad-spectrum antiviral targets; (3) a Nature Communications preclinical study shows adjunctive phage therapy synergizes with meropenem to improve o
Summary
Three high-impact studies advance respiratory infection science and preparedness: (1) a Science study establishes multi-species, multi-organ bat organoids that model zoonotic respiratory viruses and enable ex vivo antiviral testing; (2) a PNAS study maps shared human host genetic dependencies across nine respiratory viruses and validates STT3A/B as broad-spectrum antiviral targets; (3) a Nature Communications preclinical study shows adjunctive phage therapy synergizes with meropenem to improve outcomes and curb resistance in Pseudomonas ventilator-associated pneumonia.
Research Themes
- Organoid-based modeling of zoonotic respiratory viruses
- Broad-spectrum host-directed antiviral targets across respiratory viruses
- Adjunctive bacteriophage therapy to enhance antibiotics in VAP
Selected Articles
1. Diverse bat organoids provide pathophysiological models for zoonotic viruses.
This study establishes a multi-species, multi-organ bat organoid resource that recapitulates species- and tissue-specific replication of zoonotic viruses, enables isolation/characterization of bat-borne reoviruses and paramyxoviruses, and supports ex vivo testing of approved antivirals. It fills a critical gap for mechanistic studies and surveillance of respiratory and other bat viruses.
Impact: Provides a scalable experimental platform to study zoonotic respiratory viruses at the human-animal interface and to pre-test antivirals before spillover events.
Clinical Implications: While preclinical, organoid-guided antiviral testing could inform rapid response to emerging bat-borne respiratory viruses and prioritize compounds for clinical evaluation.
Key Findings
- Created a multi-species (five bat species), multi-organ (four organs) organoid panel.
- Demonstrated species- and tissue-specific replication patterns for several zoonotic viruses.
- Isolated and characterized bat-borne mammalian orthoreoviruses and paramyxoviruses using organoids.
- Tested and confirmed efficacy of known antiviral drugs against bat virus isolates ex vivo.
Methodological Strengths
- Multi-species, multi-organ organoid system enabling cross-species comparisons
- Functional readouts including virus isolation/characterization and antiviral drug testing
Limitations
- Organoids lack full immune system components and in vivo microenvironments
- Limited number of bat species/organs may not capture full biodiversity
Future Directions: Expand species and organ coverage, integrate immune co-cultures, standardize organoid banks, and link ex vivo phenotypes to in vivo spillover risk and therapeutic efficacy.
Bats are important reservoirs of zoonotic pathogens, but suitable model systems for comprehensively exploring host-pathogen interactions and assessing spillover risks remain limited. To address this gap, we developed a collection of bat organoid models spanning five species and four organ types. This multispecies, multiorgan organoid panel showed species- and tissue-specific replication patterns for several viruses, offering robust pathophysiological models for studying respiratory, renal, and enteric zoonotic viruses. Using this platform, we successfully isolated and characterized bat-borne mammalian orthoreoviruses and paramyxoviruses, demonstrating the utility of these organoid panels for virome surveillance. Furthermore, we successfully tested known antiviral drugs for their efficacy against bat virus isolates.
2. Shared host genetic landscape of respiratory viral infection.
Genome-wide CRISPR screens across nine respiratory viruses revealed shared host gene dependencies and druggable pathways. The study identified and validated STT3A/B (N-oligosaccharyltransferase complex) as broad-spectrum antiviral targets, demonstrating feasibility of host-directed antivirals.
Impact: Defines a convergent host dependency map across major respiratory viruses and delivers validated broad-spectrum targets, guiding host-directed therapeutic development.
Clinical Implications: Supports development of host-directed antivirals that may retain efficacy despite viral mutation and could be deployed against future respiratory virus outbreaks.
Key Findings
- Genome-wide CRISPR screens mapped host genes required for nine human respiratory viruses.
- Knowledge-graph analytics identified shared pathways and pharmacologic targets.
- STT3A/B of the N-oligosaccharyltransferase complex were validated as broad-spectrum antiviral targets.
- Demonstrated feasibility of small-molecule inhibition of shared host dependencies.
Methodological Strengths
- Systematic, comparative genome-wide screening across multiple viruses
- Target prioritization and validation integrating knowledge-graph analytics
Limitations
- Predominantly in vitro models without human clinical validation
- Potential cell line–specific dependencies may limit generalizability
Future Directions: Advance STT3A/B inhibitors and other shared host targets into in vivo validation and early-phase clinical trials; assess safety and antiviral breadth.
Respiratory viruses represent a major global health burden. Although these viruses have different life cycles, they may depend on common host genetic factors, which could be targeted by broad-spectrum host-directed therapies. We used genome-wide CRISPR screens and advanced data analytics to map a network of host genes that support infection by nine human respiratory viruses [influenza A virus, parainfluenza virus, human rhinovirus, respiratory syncytial virus, human coronavirus (HCoV)-229E, HCoV-NL63, HCoV-OC43, Middle East respiratory syndrome-related coronavirus, and severe acute respiratory syndrome-related coronavirus 2]. We explored shared pathways using knowledge graphs to inform on pharmacological targets. We selected and validated STT
3. Adjunctive phage therapy improves antibiotic treatment of ventilator-associated-pneumonia with Pseudomonas aeruginosa.
In a murine Pseudomonas VAP model, adding a phage cocktail to meropenem accelerated clinical improvement, protected lung epithelium, lowered meropenem’s effective concentration, and prevented resistance to both agents. Human primary epithelial cell studies corroborated synergy, supporting adjunctive phage-antibiotic strategies for MDR VAP.
Impact: Demonstrates robust preclinical synergy of phages with carbapenems for VAP, addressing efficacy and resistance barriers that limited phage monotherapy.
Clinical Implications: Supports rational design of clinical trials testing phage-antibiotic combinations in MDR Pseudomonas VAP, with potential to reduce antibiotic dosing and resistance emergence.
Key Findings
- Adjunctive phage plus meropenem accelerated clinical improvement in a murine VAP model.
- Combination therapy prevented lung epithelial cell damage compared with monotherapies.
- In human primary epithelial cells, phage addition reduced meropenem’s minimum effective concentration.
- Combination prevented resistance against both phages and meropenem.
Methodological Strengths
- In vivo murine VAP model complemented by human primary epithelial cell assays
- Direct assessment of synergy, epithelial protection, and resistance emergence
Limitations
- Single-pathogen focus (Pseudomonas aeruginosa) may limit generalizability
- Preclinical study without human clinical outcomes or pharmacokinetic optimization
Future Directions: Design dose-finding and safety trials of phage–antibiotic combinations in MDR VAP; explore spectrum across pathogens and optimize dosing schedules to minimize resistance.
Bacterial multidrug resistance poses an urgent challenge for the treatment of critically ill patients developing ventilator-associated pneumonia (VAP). Phage therapy, a potential alternative when conventional antibiotics fail, has been unsuccessful in first clinical trials when used alone. Whether combining antibiotics with phages may enhance effectiveness remains to be tested in experimental models. Here, we use a murine model of Pseudomonas-induced VAP to compare the efficacy of adjunctive phage cocktail for antibiotic therapy to either meropenem or phages alone. Combined treatment in murine VAP results in faster clinical improvement and prevents lung epithelial cell damage. Using human primary epithelial cells to dissect these synergistic effects, we find that adjunctive phage therapy reduces the minimum effective concentration of meropenem and prevents resistance development against both treatments. These findings suggest adjunctive phage therapy represents a promising treatment for MDR-induced VAP, enhancing the effectiveness of both antibiotics and phages while reducing adverse effects.